Compare Adaptive Biotechnologies Corp (ADPT) vs iShares Core US Aggregate Bond ETF (AGG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares Core US Aggregate Bond ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.98 (market cap $4.05B), while iShares Core US Aggregate Bond ETF trades at $97.34. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, iShares Core US Aggregate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | AGG | |
|---|---|---|
Market Cap | $4.05B | — |
Sector | Health | Fixed Income |
52-Week High | $25.45 | $101.40 |
52-Week Low | $12.30 | $97.24 |
Enterprise Value | $4.12B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.93, up 5.64% in 24 hours and near its 52-week high. The stock shows bullish technical momentum with improving fundamentals as revenue grew 55% year-over-year to $277M in 2025 while net losses narrowed significantly from -$159M to -$59M. The company's strategic shift to focus on its profitable MRD diagnostics business through a planned separation of Immune Medicine operations has driven investor optimism.
Outlook remains cautiously optimistic as ADPT transitions to a pure-play MRD company with strong gross margins exceeding 75%. While analyst consensus favors Buy ratings (65%), persistent net losses and high valuation multiples (P/S 12.6x, P/B 27.8x) present risks. The $25.50 price target suggests limited upside from current levels amid execution risks.
AGG trades at $97.6, up 0.17% on the day, with a neutral technical signal and bearish moving averages. Recent news highlights institutional accumulation and bond ETF inflows amid fluctuating Treasury yields. The ETF offers consistent dividends, with the latest payments scheduled for 2026.
Outlook remains tied to interest rate trends and inflation data, presenting income stability but facing pressure from rising yields. Key risks include Fed policy shifts and geopolitical impacts on oil prices, while institutional buying signals confidence in fixed-income appeal.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares Core US Aggregate Bond ETF
AGG tracks the Bloomberg U.S. Aggregate Bond Index, providing broad exposure to the total U.S. investment-grade bond market. It serves as a core portfolio building block by diversifying across Treasuries, government-related bonds, corporate debt, and mortgage-backed securities.
Read more on AGG →
